Business Segment Information (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and six months ended June 30, 2022 and 2021, and asset information as of June 30, 2022 and December 31, 2021:

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Net revenues:
Diagnostics	$	60,455		$	19,311		$	98,765		$	33,857
Molecular Solutions		19,776			38,296			49,173			82,332
Total	$	80,231		$	57,607		$	147,938		$	116,189
Operating income (loss):
Diagnostics	$	(11,776	)	$	(11,850	)	$	(31,563	)	$	(23,967	)
Molecular Solutions		(9,513	)		13,648			(5,704	)		36,187
Total	$	(21,289	)	$	1,798		$	(37,267	)	$	12,220
Depreciation and amortization:
Diagnostics	$	1,903		$	939		$	3,630		$	1,829
Molecular Solutions		1,879			1,716			3,834			3,315
Total	$	3,782		$	2,655		$	7,464		$	5,144
Loss on impairment:
Diagnostics	$	8,517		$	—		$	8,517		$	—
Molecular Solutions		2,025			—			2,025			—
Total	$	10,542		$	—		$	10,542		$	—
Capital expenditures:
Diagnostics(1)	$	4,302		$	8,513		$	23,434		$	16,150
Molecular Solutions		919			3,355			2,006			6,779
Total	$	5,221		$	11,868		$	25,440		$	22,929

(1) Excludes $5,615 and $33,803 for purchases of property and equipment under government contracts for the three and six months ended June 30, 2022, respectively.

	June 30, 2022		December 31, 2021
Total assets:
Diagnostics	$	249,123	$	209,674
Molecular Solutions		180,131		251,316
Total	$	429,254	$	460,990